Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Bristol-Myers Squibb Company Ce

Bristol-Myers Squibb Company Ce (CELG-RI) Stock Overview

Explore Bristol-Myers Squibb Company Ce’s financial performance, market position, analyst ratings, and future outlook.

CELG-RI●NYSE
HealthcareMedical - Pharmaceuticals
$0.12
$0.02(21.21%)
U.S. Market opens in 14h 4m

Bristol-Myers Squibb Company Ce (CELG-RI)

Meyka AI Score

Z

Key Financials

Market Cap245.1M
P/E Ratio0.03
EPS (TTM)N/A
ROE0.47%
Fundamental Analysis

AI Price Forecasts

1 Month$0.12
3 Months$0.15
1 Year Target$0.15

CELG-RI Stock Analysis & Investment Overview (NYSE)

Our AI-powered analysis of Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) gives investors deep insight into how the stock performs on the NYSE exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Bristol-Myers Squibb Company Ce's NYSE-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of CELG-RI on the NYSE shows an RSI of 52.97, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $0.15 for the NYSE listing.

Key metrics behind Bristol-Myers Squibb Company Ce's NYSE-traded stock include a P/E ratio of 0.03 and a market capitalization of 245.1M. Combined with our AI analysis, these give both institutional and retail investors a clear view of CELG-RI on the NYSE.

Price Performance (NYSE: CELG-RI)

1-Day Change
21.21%
5-Day Change
21.21%
1-Month Change
11.008%
3-Month Change
15.38%
6-Month Change
20.12%
Year-to-Date (YTD) Change
66.90%
1-Year Change
283.39%
3-Year Change
41.01%
5-Year Change
-22.53%
All-Time (Max) Change
-22.53%

Contact Information

http://www.bms.com
+1 609 252 4000
Route 206 & Province Line Road, Princeton, NJ, 8543

Company Facts

341,000 Employees
IPO DateNov 21, 2019
CountryUS
Actively Trading

Frequently Asked Questions